This is an exploratory clinical study evaluating the safety and initial efficacy of BGT007 injection in the treatment of recurrent/metastatic/refractory digestive system tumors
Voluntarily sign a written informed consent.
Age ≥18 years old, ≤70 years old, male and female.
Expected survival ≥ 3 months.
The Eastern Cancer Collaboration (ECOG) physical fitness score was 0-1.
Active central nervous system metastases (except those stable after treatment).
HIV positive, HBsAg positive, HBV DNA copy number positive (quantitative detection ≥1000cps/ml), HCV antibody positive and HCV RNA positive.
Patients with mental or mental illness who cannot cooperate with treatment and efficacy evaluation.
Subjects with severe autoimmune diseases and long-term use of immunosuppressants.
The Affiliated Hospital of Xuzhou Medical University
Lead sponsor
Guangzhou Bioresette Biomedical Technology Co., Ltd.
Collaborator